首页> 外文期刊>Research and Reports in Urology >Prostatic artery embolization versus transurethral resection of the prostate in the treatment of benign prostatic hyperplasia: protocol for a non-inferiority clinical trial
【24h】

Prostatic artery embolization versus transurethral resection of the prostate in the treatment of benign prostatic hyperplasia: protocol for a non-inferiority clinical trial

机译:前列腺动脉栓塞与经尿道前列腺切除术治疗良性前列腺增生:一项非劣效性临床试验的方案

获取原文
           

摘要

Background: Benign prostatic hyperplasia (BPH) is a prevalent disease associated with lower urinary tract symptoms (LUTS). The standard of care for moderate-to-severe LUTS unresponsive to pharmacological treatment is the transurethral resection of the prostate (TURP). However, this intervention is not exempt from complications. Prostatic artery embolization (PAE) has been described as a new, effective and safe procedure for the treatment of LUTS secondary to BPH. To date, only one clinical trial has been published on the use of PAE for LUTS, but the study was methodologically flawed in terms of safety monitoring. Therefore, well-designed clinical studies are required to compare the efficacy and safety of both techniques in the treatment of LUTS secondary to BPH. Methods and design: This was a prospective, randomized, non-inferiority clinical trial comparing efficacy and safety of PAE and TURP in the treatment of BPH-related LUTS. A total of 60 patients diagnosed with BPH with obstructive moderate or severe LUTS refractory to medical therapy and candidates for TURP were randomized to either PAE or TURP. The presence and severity of LUTS were assessed using the validated Spanish version of the International Prostate Symptom Score (IPSS). Primary end points included improvement in maximum urinary flow rate ( Q max) as measured at baseline and 1?year after the intervention. Improvement in IPSS as measured at baseline and after the intervention, reduction in prostate volume, no deterioration or improvement of sexual function (International Index of Erectile Function [IIEF]), reduction in PSA and PVR, satisfaction of the patient with the operation and adverse events occurring during the study were secondary outcome measures. Discussion: The aim of this clinical study was to investigate whether PAE is a valid therapeutic option for LUTS that is not inferior to TURP in terms of efficacy and safety. This study also helped to define the profile of candidates for PAE and analyzed the benefits and complications associated with this new technique.
机译:背景:良性前列腺增生(BPH)是与下尿路症状(LUTS)相关的普遍疾病。对药物治疗无反应的中度至重度LUTS的护理标准是经尿道前列腺电切术(TURP)。但是,这种干预措施不能免除并发症。前列腺动脉栓塞术(PAE)被描述为治疗继发于BPH的LUTS的一种新型,有效和安全的方法。迄今为止,仅发表了一项关于将PAE用于LUTS的临床试验,但是该研究在安全性监控方面存在方法上的缺陷。因此,需要精心设计的临床研究来比较两种技术在治疗BPH继发性LUTS中的有效性和安全性。方法和设计:这是一项前瞻性,随机,非劣效性临床试验,比较了PAE和TURP在治疗BPH相关的LUTS中的功效和安全性。总共60例诊断为BPH的阻塞性中度或重度LUTS对药物治疗无效的患者和TURP候选人被随机分为PAE或TURP。使用经验证的西班牙国际前列腺症状评分(IPSS)版本评估LUTS的存在和严重程度。主要终点包括基线时和干预后1年测量的最大尿流率(Q max )的改善。基线和干预后IPSS的改善,前列腺体积的减少,性功能没有恶化或改善(国际勃起功能指数[IIEF]),PSA和PVR降低,患者对手术的满意度和不良反应研究期间发生的事件是次要结果指标。讨论:这项临床研究的目的是研究PAE是否对LUTS有效,在疗效和安全性方面不逊于TURP。这项研究还有助于确定PAE候选人的概况,并分析了与这项新技术相关的益处和并发症。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号